Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tebufelone is a small molecule nonsteroidal anti-inflammatory drug (NSAID) of the di-tert-butyl-phenol class, developed as a dual cyclooxygenase (COX)/5-lipoxygenase (5-LOX) inhibitor. It exhibits potent analgesic, antipyretic, and anti-inflammatory activities in preclinical and clinical models. Its mechanism of action involves reversible inhibition of both cyclooxygenase and 5-lipoxygenase enzymes, leading to decreased synthesis of prostaglandins and leukotrienes, respectively. Tebufelone was studied primarily for rheumatic disorders and pain but its development was discontinued after phase II clinical trials, likely due to safety or efficacy concerns[1][3][4][6][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tebufelone.